Which has higher earnings & valuation, WRBY or BVS?

Bioventus has lower revenue, but higher earnings than Warby Parker. Bioventus is trading at a lower price-to-earnings ratio than Warby Parker, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Warby Parker $871.91M 3.23 $1.64M $0.02 1,316.20 Bioventus $568.09M 1.25 $22.73M $0.41 20.76

Is WRBY or BVS more profitable?

Bioventus has a net margin of 4.94% compared to Warby Parker's net margin of 0.15%. Bioventus' return on equity of 29.97% beat Warby Parker's return on equity. Company Net Margins Return on Equity Return on Assets Warby Parker 0.15% 2.30% 1.18% Bioventus 4.94% 29.97% 9.52%

Does the media refer more to WRBY or BVS?

In the previous week, Warby Parker had 1 more articles in the media than Bioventus. MarketBeat recorded 5 mentions for Warby Parker and 4 mentions for Bioventus. Bioventus' average media sentiment score of 1.00 beat Warby Parker's score of 0.33 indicating that Bioventus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Warby Parker 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bioventus 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, BVS or TMDX?

TransMedics Group has higher revenue and earnings than Bioventus. TransMedics Group is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bioventus $568.09M 1.25 $22.73M $0.41 20.76 TransMedics Group $605.49M 4.16 $190.29M $4.40 16.57

Does the media favor BVS or TMDX?

In the previous week, Bioventus and Bioventus both had 4 articles in the media. Bioventus' average media sentiment score of 1.00 beat TransMedics Group's score of 0.55 indicating that Bioventus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bioventus 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TransMedics Group 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has better valuation & earnings, BVS or AXGN?

Bioventus has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bioventus $568.09M 1.25 $22.73M $0.41 20.76 AxoGen $225.21M 10.15 -$15.70M -$0.64 N/A

Is BVS or AXGN more profitable?

Bioventus has a net margin of 4.94% compared to AxoGen's net margin of -13.21%. Bioventus' return on equity of 29.97% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets Bioventus 4.94% 29.97% 9.52% AxoGen -13.21% -9.63% -6.26%

Does the media prefer BVS or AXGN?

In the previous week, Bioventus had 2 more articles in the media than AxoGen. MarketBeat recorded 4 mentions for Bioventus and 2 mentions for AxoGen. AxoGen's average media sentiment score of 1.84 beat Bioventus' score of 1.00 indicating that AxoGen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bioventus 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AxoGen 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has higher earnings and valuation, BVS or ESTA?

Bioventus has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bioventus $568.09M 1.25 $22.73M $0.41 20.76 Establishment Labs $211.08M 11.45 -$51.06M -$1.49 N/A

Does the media prefer BVS or ESTA?

In the previous week, Bioventus had 2 more articles in the media than Establishment Labs. MarketBeat recorded 4 mentions for Bioventus and 2 mentions for Establishment Labs. Bioventus' average media sentiment score of 1.00 beat Establishment Labs' score of 0.94 indicating that Bioventus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bioventus 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Establishment Labs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BVS or LMAT?

In the previous week, Bioventus and Bioventus both had 4 articles in the media. LeMaitre Vascular's average media sentiment score of 1.44 beat Bioventus' score of 1.00 indicating that LeMaitre Vascular is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bioventus 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LeMaitre Vascular 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Bioventus (BVS) Competitors

$8.51 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$8.52 +0.01 (+0.06%)

As of 06/12/2026 05:39 PM Eastern

Compare

BVS vs. WRBY, TMDX, AXGN, ESTA, and LMAT

Should you buy Bioventus stock or one of its competitors? MarketBeat compares Bioventus with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bioventus include Warby Parker (WRBY), TransMedics Group (TMDX), AxoGen (AXGN), Establishment Labs (ESTA), and LeMaitre Vascular (LMAT). These companies are all part of the "medical equipment" industry.

How does Bioventus compare to Warby Parker?

Warby Parker (NYSE:WRBY) and Bioventus (NASDAQ:BVS) are both medical equipment companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability and institutional ownership.

Warby Parker has a beta of 1.96, suggesting that its stock price is 96% more volatile than the broader market. Comparatively, Bioventus has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market.

93.2% of Warby Parker shares are owned by institutional investors. Comparatively, 62.9% of Bioventus shares are owned by institutional investors. 16.8% of Warby Parker shares are owned by company insiders. Comparatively, 33.0% of Bioventus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Warby Parker had 1 more articles in the media than Bioventus. MarketBeat recorded 5 mentions for Warby Parker and 4 mentions for Bioventus. Bioventus' average media sentiment score of 1.00 beat Warby Parker's score of 0.33 indicating that Bioventus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Warby Parker	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bioventus	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bioventus has a net margin of 4.94% compared to Warby Parker's net margin of 0.15%. Bioventus' return on equity of 29.97% beat Warby Parker's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Warby Parker	0.15%	2.30%	1.18%
Bioventus	4.94%	29.97%	9.52%

Bioventus has lower revenue, but higher earnings than Warby Parker. Bioventus is trading at a lower price-to-earnings ratio than Warby Parker, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Warby Parker	$871.91M	3.23	$1.64M	$0.02	1,316.20
Bioventus	$568.09M	1.25	$22.73M	$0.41	20.76

Warby Parker presently has a consensus price target of $29.50, suggesting a potential upside of 12.07%. Bioventus has a consensus price target of $14.00, suggesting a potential upside of 64.51%. Given Bioventus' stronger consensus rating and higher probable upside, analysts clearly believe Bioventus is more favorable than Warby Parker.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Warby Parker	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.64
Bioventus	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Bioventus beats Warby Parker on 10 of the 17 factors compared between the two stocks.

How does Bioventus compare to TransMedics Group?

Bioventus (NASDAQ:BVS) and TransMedics Group (NASDAQ:TMDX) are both medical equipment companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

62.9% of Bioventus shares are held by institutional investors. Comparatively, 99.7% of TransMedics Group shares are held by institutional investors. 33.0% of Bioventus shares are held by insiders. Comparatively, 6.9% of TransMedics Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Bioventus and Bioventus both had 4 articles in the media. Bioventus' average media sentiment score of 1.00 beat TransMedics Group's score of 0.55 indicating that Bioventus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TransMedics Group	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Bioventus presently has a consensus target price of $14.00, suggesting a potential upside of 64.51%. TransMedics Group has a consensus target price of $134.00, suggesting a potential upside of 83.79%. Given TransMedics Group's higher possible upside, analysts clearly believe TransMedics Group is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
TransMedics Group	0 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.46

TransMedics Group has a net margin of 27.04% compared to Bioventus' net margin of 4.94%. Bioventus' return on equity of 29.97% beat TransMedics Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	4.94%	29.97%	9.52%
TransMedics Group	27.04%	22.38%	8.46%

TransMedics Group has higher revenue and earnings than Bioventus. TransMedics Group is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$568.09M	1.25	$22.73M	$0.41	20.76
TransMedics Group	$605.49M	4.16	$190.29M	$4.40	16.57

Bioventus has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market. Comparatively, TransMedics Group has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market.

Summary

TransMedics Group beats Bioventus on 9 of the 16 factors compared between the two stocks.

How does Bioventus compare to AxoGen?

Bioventus (NASDAQ:BVS) and AxoGen (NASDAQ:AXGN) are both medical equipment companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.

Bioventus has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market. Comparatively, AxoGen has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market.

Bioventus presently has a consensus price target of $14.00, suggesting a potential upside of 64.51%. AxoGen has a consensus price target of $46.50, suggesting a potential upside of 8.14%. Given Bioventus' stronger consensus rating and higher probable upside, equities research analysts clearly believe Bioventus is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, Bioventus had 2 more articles in the media than AxoGen. MarketBeat recorded 4 mentions for Bioventus and 2 mentions for AxoGen. AxoGen's average media sentiment score of 1.84 beat Bioventus' score of 1.00 indicating that AxoGen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AxoGen	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Bioventus has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$568.09M	1.25	$22.73M	$0.41	20.76
AxoGen	$225.21M	10.15	-$15.70M	-$0.64	N/A

62.9% of Bioventus shares are held by institutional investors. Comparatively, 80.3% of AxoGen shares are held by institutional investors. 33.0% of Bioventus shares are held by company insiders. Comparatively, 2.4% of AxoGen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Bioventus has a net margin of 4.94% compared to AxoGen's net margin of -13.21%. Bioventus' return on equity of 29.97% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	4.94%	29.97%	9.52%
AxoGen	-13.21%	-9.63%	-6.26%

Summary

Bioventus beats AxoGen on 12 of the 17 factors compared between the two stocks.

How does Bioventus compare to Establishment Labs?

Bioventus (NASDAQ:BVS) and Establishment Labs (NASDAQ:ESTA) are both medical equipment companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

Bioventus has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market. Comparatively, Establishment Labs has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market.

In the previous week, Bioventus had 2 more articles in the media than Establishment Labs. MarketBeat recorded 4 mentions for Bioventus and 2 mentions for Establishment Labs. Bioventus' average media sentiment score of 1.00 beat Establishment Labs' score of 0.94 indicating that Bioventus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Establishment Labs	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bioventus has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$568.09M	1.25	$22.73M	$0.41	20.76
Establishment Labs	$211.08M	11.45	-$51.06M	-$1.49	N/A

Bioventus has a net margin of 4.94% compared to Establishment Labs' net margin of -19.05%. Bioventus' return on equity of 29.97% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	4.94%	29.97%	9.52%
Establishment Labs	-19.05%	-218.77%	-12.31%

Bioventus presently has a consensus target price of $14.00, suggesting a potential upside of 64.51%. Establishment Labs has a consensus target price of $87.14, suggesting a potential upside of 6.09%. Given Bioventus' stronger consensus rating and higher probable upside, research analysts plainly believe Bioventus is more favorable than Establishment Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

62.9% of Bioventus shares are held by institutional investors. Comparatively, 72.9% of Establishment Labs shares are held by institutional investors. 33.0% of Bioventus shares are held by company insiders. Comparatively, 10.0% of Establishment Labs shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Bioventus beats Establishment Labs on 13 of the 17 factors compared between the two stocks.

How does Bioventus compare to LeMaitre Vascular?

Bioventus (NASDAQ:BVS) and LeMaitre Vascular (NASDAQ:LMAT) are both medical equipment companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

Bioventus has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market. Comparatively, LeMaitre Vascular has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market.

62.9% of Bioventus shares are owned by institutional investors. Comparatively, 84.6% of LeMaitre Vascular shares are owned by institutional investors. 33.0% of Bioventus shares are owned by insiders. Comparatively, 7.4% of LeMaitre Vascular shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Bioventus currently has a consensus price target of $14.00, indicating a potential upside of 64.51%. LeMaitre Vascular has a consensus price target of $112.60, indicating a potential upside of 22.44%. Given Bioventus' stronger consensus rating and higher possible upside, equities analysts clearly believe Bioventus is more favorable than LeMaitre Vascular.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
LeMaitre Vascular	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Bioventus and Bioventus both had 4 articles in the media. LeMaitre Vascular's average media sentiment score of 1.44 beat Bioventus' score of 1.00 indicating that LeMaitre Vascular is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LeMaitre Vascular	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LeMaitre Vascular has lower revenue, but higher earnings than Bioventus. Bioventus is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$568.09M	1.25	$22.73M	$0.41	20.76
LeMaitre Vascular	$249.60M	8.42	$57.73M	$2.71	33.93

LeMaitre Vascular has a net margin of 24.35% compared to Bioventus' net margin of 4.94%. Bioventus' return on equity of 29.97% beat LeMaitre Vascular's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	4.94%	29.97%	9.52%
LeMaitre Vascular	24.35%	15.36%	9.78%

Summary

LeMaitre Vascular beats Bioventus on 9 of the 15 factors compared between the two stocks.

Get Bioventus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BVS vs. The Competition

Export

Metric	Bioventus	Surgical, Medical, And Dental Instruments And Supplies Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$710.93M	$2.78B	$4.91B	$12.07B
Dividend Yield	N/A	N/A	10.25%	5.67%
P/E Ratio	20.76	12.29	22.22	24.42
Price / Sales	1.25	334.04	159.46	109.94
Price / Cash	6.67	8.03	40.19	37.92
Price / Book	3.08	5.47	26.92	6.83
Net Income	$22.73M	$7.39M	$116.61M	$337.67M
7 Day Performance	-4.92%	-3.57%	0.25%	1.17%
1 Month Performance	-19.57%	-2.76%	0.25%	3.16%
1 Year Performance	N/A	12.97%	14.23%	30.58%

Bioventus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BVS Bioventus	4.4627 of 5 stars	$8.51 flat	$14.00 +64.5%	N/A	$710.93M	$568.09M	20.76	1,200	Positive News Gap Up
WRBY Warby Parker	3.42 of 5 stars	$22.69 -5.9%	$29.50 +30.0%	+19.4%	$2.58B	$871.91M	1,134.92	4,036	News Coverage Insider Trade
TMDX TransMedics Group	4.4006 of 5 stars	$69.43 -2.7%	$134.00 +93.0%	-49.0%	$2.47B	$605.49M	15.78	210
AXGN AxoGen	2.0112 of 5 stars	$42.80 +1.0%	$46.50 +8.6%	+341.0%	$2.25B	$225.21M	N/A	450	Positive News
ESTA Establishment Labs	1.5448 of 5 stars	$74.31 -2.9%	$87.14 +17.3%	+119.4%	$2.25B	$211.08M	N/A	1,004

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BVS) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bioventus (BVS) Competitors

BVS vs. WRBY, TMDX, AXGN, ESTA, and LMAT

How does Bioventus compare to Warby Parker?

Summary

How does Bioventus compare to TransMedics Group?

Summary

How does Bioventus compare to AxoGen?

Summary

How does Bioventus compare to Establishment Labs?

Summary

How does Bioventus compare to LeMaitre Vascular?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BVS vs. The Competition

Bioventus Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bioventus (BVS) Competitors

BVS vs. WRBY, TMDX, AXGN, ESTA, and LMAT

How does Bioventus compare to Warby Parker?

Which has more risk and volatility, WRBY or BVS?

Do insiders & institutionals hold more shares of WRBY or BVS?

Does the media refer more to WRBY or BVS?

Is WRBY or BVS more profitable?

Which has higher earnings & valuation, WRBY or BVS?

Do analysts recommend WRBY or BVS?

Summary

How does Bioventus compare to TransMedics Group?

Do insiders and institutionals have more ownership in BVS or TMDX?

Does the media favor BVS or TMDX?

Do analysts rate BVS or TMDX?

Is BVS or TMDX more profitable?

Which has higher valuation and earnings, BVS or TMDX?

Which has more risk and volatility, BVS or TMDX?

Summary

How does Bioventus compare to AxoGen?

Which has more volatility and risk, BVS or AXGN?

Do analysts rate BVS or AXGN?

Does the media prefer BVS or AXGN?

Which has better valuation & earnings, BVS or AXGN?

Do institutionals & insiders hold more shares of BVS or AXGN?

Is BVS or AXGN more profitable?

Summary

How does Bioventus compare to Establishment Labs?

Which has more risk & volatility, BVS or ESTA?

Does the media prefer BVS or ESTA?

Which has higher earnings and valuation, BVS or ESTA?

Is BVS or ESTA more profitable?

Do analysts rate BVS or ESTA?

Do insiders & institutionals hold more shares of BVS or ESTA?

Summary

How does Bioventus compare to LeMaitre Vascular?

Which has more volatility and risk, BVS or LMAT?

Do insiders and institutionals believe in BVS or LMAT?

Do analysts prefer BVS or LMAT?

Does the media favor BVS or LMAT?

Which has stronger valuation & earnings, BVS or LMAT?

Is BVS or LMAT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BVS vs. The Competition

Bioventus Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools